Effects on host of modified PVP therapy combined with biological response modifiers in lung cancer

Oncology Reports

Volumn 5, Issue 1, 1998, Pages 103-107

  Katoh, R ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

Biological response modifiers; Chemotherapy; Immunosuppressive acid protein; Lung cancer; sIL 2R

Indexed keywords

CARBOPLATIN; ETOPOSIDE; INTERLEUKIN 2 RECEPTOR; KRESTIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG POTENTIATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG LOBECTOMY; LUNG SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RECURRENCE RISK; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0031985420     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.1.103     Document Type: Article

References (2)

1. Einhorn LH, Crowford J and Birch R: Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin and vincristine in limited small-cell lung cancer. J Clin Oncol 5: 1401-1409, 1987.
2. Feld R, Evans WK, Coy P, Hodson I, MacDonald AS, Osoba D, Payne D, Shelley W and Pater JL: Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross resistant chemotherapy combination in patients with limited small-cell carcinoma of the lung. J Clin Oncol 5: 1401-1409, 1987.